Meeting
2016 Gastrointestinal Cancers Symposium
RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).
Authors
Andrew H. Ko
University of California, San Francisco, San Francisco, CA
Andrew H. Ko , Patrick B. Murphy , James D. Peyton , Dianna Shipley , Ahmed Al-Hazzouri , Frank A. Rodriguez , Mark S. Womack IV, Henry Q. Xiong , David M. Waterhouse , Margaret A. Tempero , Johanna C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01844817
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 419)
DOI
10.1200/jco.2016.34.4_suppl.419
Abstract #
419
Poster Bd #
L13
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.
First Author: Johanna C. Bendell
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2018 Gastrointestinal Cancers Symposium
A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.
First Author: Johanna C. Bendell
Poster
2014 Gastrointestinal Cancers Symposium
Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
First Author: Ramesh K. Ramanathan